LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

missed 'last months report' entirely, did anyone actually see it/read it?

no move on price today seems odd, given the Times report and this article......

outlook123 - 08 Sep 2007 17:18 - 31 of 41

Chat on iii board suggests that an announcement is due by the end of this month.

Also, tipped in "Shares" magazine this week:-

http://www.sharesmagazine.com/node/1227

Thanks for that info in 40 above, Outlook123 . Can't be long now!

RNS today:
Provexis PLC
14 November 2007

Provexis and Unilever renew Fruitflow(R) Exclusivity Agreement
Provexis, developer of scientifically-proven functional food, dietary supplement
and medical food technologies, announces that it has progressed its exclusivity
agreement with Unilever plc on to look specifically at how Provexis might
develop a new format of its patented Fruitflow(R) heart-health technology for
potential application in Unilever's spread product portfolio.

Fruitflow(R) is a patented natural extract from tomato which has been shown in
human trials to reduce the propensity for aberrant blood clotting, typically
associated with cardiovascular disease, which can lead to heart attack or
stroke. Unilever has substantial global brands in the heart-health market,
primarily its Flora/Becel spreads and drinking yoghurts, which have sales in
excess of 1bn.

The partners have successfully developed a pilot-scale version of the new
concentrated format over the past year, which subsequently showed positive
results in a recent human trial. Under the terms of new agreement, which extends
for 12 months, Provexis will now further develop this new technology to deliver
a product suitable for potential incorporation into vegetable-oil based fat
spreads. Unilever will transfer certain manufacturing assets to Provexis to
facilitate this phase of the project.

There are four sectors in which Provexis is seeking major partnerships, namely,
food and dairy, beverages, products for deep vein thrombosis, and dietary
supplements and medical products.

Commenting on the renewal of the collaboration agreement, Stephen Moon, CEO of
Provexis, said: 'We are pleased with the progress made over the last year and
are now focusing on delivering this important new format in a product suitable
for Unilever's spread range.'

http://www.foodnavigator.com/news/ng.asp?n=81375-unilever-provexis-fruitflow-spreads

Interesting article - many thanks for the link, Outlook.

Provexis PLC
15 November 2007

For release at 07.00 16 November 2007


PROVEXIS plc
('Provexis' or the 'Company')

EXCLUSIVE FRUITFLOW(R) TECHNOLOGY ASSESSMENT AGREEMENT WITH THE COCA-COLA
COMPANY

Provexis plc (PXS.L), which discovers, develops and licenses
scientifically-proven functional food, medical food and dietary supplement
technologies, announces the signing of a 12 month exclusive technology
assessment agreement for its patented Fruitflow(R) anti-thrombotic technology
with The Coca-Cola Company.

The exclusivity agreement covers all beverages, with the exception of
mini-drinks. During the assessment period both parties will carry out a
programme of work including consumer testing, commercial assessment and
finalising regulatory approval in a range of territories. Subject to positive
results in these areas, the parties intend to proceed to a licensing agreement
during the period of exclusivity.

There are four sectors in which Provexis is seeking major partnerships, namely,
food and dairy, beverages, products for deep vein thrombosis, and dietary
supplements and medical products. The Company has an existing collaboration
agreement with Unilever for certain formats within the food and dairy sectors.

Oh wow!!! This is one of the things we thought was going. Great news!

Toya: feel free to join-in on the ADVFN board, which is quite lively.

I'll have a read of that - thanks. I'd put PXS forward on the list here for '10-baggers'. If these assessments work through to production, then I think we could well get there.

I agree - if they get through the 'cash burn' stage to receiving actual revenue from Coke and / or Unilever then they could easily be a 10-bagger IMHO.

.

Cool! it's all coming on nicely.....onwards and upwards! might top up on any sp weakness in the coming weeks while waiting for more news.

Can't be bad....2 bits of good news in one day..!....NPE looking good also!

This is bloody good news the sp should be way up today!!!!!! come on

From AFX NEwsfeed today:

Provexis H1 pretax loss narrows; sees continued progress in rest of year

AFX LONDON (Thomson Financial) - Provexis PLC narrowed its first-half pretax loss and said it expects the positive trend to continue for the remainder of the year.The maker of nutrition products posted pretax loss of 661,221 stg compared with 758,148 stg a year ago. Adjusted loss before interest, share compensation expense and tax of narrowed to 753,000 stg versus 1.4 mln stg a year earlier.Revenue fell to 60,936 stg compared with 66,653 stg a year earlier.TFN.newsdesk@thomson.com

http://www.foodnavigator.com/news/ng.asp?n=81442-provexis-coca-cola-unilever-fruitflow

http://www.dailystar.co.uk/news/view/22666/Drink-stops-blood-clots-/?printer=1

Also mentioned in today's Daily Telegraph (tiny paragraph p.12)

This recieved frim Peter Shearlock's stock pickes this morning...

Provexis a steal at under £10 million

The harsh treatment meted out to AIM stocks in the past six months has one positive aspect: it gives incoming investors a second chance to climb aboard interesting stocks at bargain basement levels. Provexis, the life sciences business that is developing food and dietary supplements, is a case in point. Its shares touched 5.5p in the summer. Today they are back to 2.38p – which is where they were before a couple of breakthrough deals were announced with multinationals to commercialise Provexis’ technology. The company is now valued at just £9.5 million. That is option money in the context of where Provexis could be in a few years’ time.

Provexis’ flagship technology is in a food supplement called Fruitflow which helps combat thrombosis and improves heart health. The company is looking to commercialise Fruitflow in four areas: food and dairy products, beverages, products for deep vein thrombosis, and dietary supplements and medical products. In the past year it has tied up a deal with Unilever, the giant food and household products business, to develop Fruitflow for the global spreads market. In November last year, it announced a similar deal with Coca-Cola for the beverages market.

They say you can judge people by the company they keep. Provexis is certainly moving in the right circles and there is every chance of more deals with top names in the current year. Fruitflow will also enter human trials aimed at furthering claims for the product in countering deep vein thrombosis this year. A second technology, for combating Crohn’s disease, is similarly entering human trials.

There is a more focused feel to Provexis since the former commercial director, Stephen Moon, took over as chief executive 18 months ago. He in turn brought in a new finance director last year. A business selling Fruitflow in a drink called Sirco has been closed down and the rights transferred to a third party. Provexis is now concentrating on developing its food and dietary technologies and finding new ones it can add to the pipeline. Two new people have been added to the research team.

At the last count, Provexis still had just over £1 million in the bank, having raised £1.86 million net in a placing last April. The next figures should show a reduced cash burn following the exit from Sirco and other restructuring moves.

The pull-back in the Provexis share price over the autumn and winter represents a tremendous opportunity to buy into a business that is just on the verge of commercialising its technology – and where the upside is huge. If you have the patience to stay with this one for a two or three-year haul it should reward you handsomely. Buy.

Anybody have any ideas on the 6% rise today? Thanks in advance.

No idea blanche - but long may it last! Almost forgot I hold a few of these... time it woke up.